The pharmaceutical giant Eli Lilly has once again raised the bar in the highly competitive obesity treatment market. New clinical trial data for its experimental drug Retatrutid has delivered results that surpass all existing therapies, potentially redefining the standard of care. As rivals work to catch up with current blockbusters, Lilly’s candidate is approaching a staggering 30% average weight reduction, prompting analysts to question whether main competitor Novo Nordisk can match this pace of innovation.
Unprecedented Efficacy Data Emerges
On Thursday, Eli Lilly unveiled findings from its “TRIUMPH-4” Phase 3 study. The figures are striking: at the highest dose of 12 mg, Retatrutid achieved an average weight loss of 28.7 percent over 68 weeks. The placebo group, by contrast, showed only a 2.1 percent reduction.
These results not only stand alone as impressive but also significantly outperform current market leaders. Lilly’s own approved drug, Zepbound, yields an average of about 21 percent weight loss, while Novo Nordisk’s Wegovy comes in at approximately 15 percent. Market observers, including David Risinger of Leerink Partners, noted that Lilly appears to have developed the medication with the “best weight loss efficacy results to date.”
The drug’s mechanism is central to its performance. Retatrutid is classified as a “triple G” agonist, meaning it simultaneously stimulates three hormone receptors—GLP-1, GIP, and glucagon. Existing treatments typically target only one or two of these pathways.
Wall Street Reacts with Revised Targets
The financial community responded swiftly, with several analyst firms lifting their price targets for Eli Lilly shares. Wells Fargo raised its target to $1,200, while Wolfe Research set an even higher expectation of $1,250.
Should investors sell immediately? Or is it worth buying Eli Lilly?
Experts point out that Lilly’s dominance extends beyond obesity treatment. The recent study also demonstrated significant improvements for patients with knee osteoarthritis—a substantial additional benefit that could facilitate future insurance coverage and reimbursement. Notably, over one-eighth of the trial participants reported being completely free of knee pain by the study’s conclusion.
Despite the strong long-term outlook, the stock showed a muted reaction in recent trading, with shares at 865.60 Euros (down 0.10 percent). Following a recent rally, the market seems to be digesting the news, especially considering the stock has already gained more than 14 percent year-to-date.
Side Effects and Regulatory Pathway
As is common with this class of medication, the new drug candidate is not without side effects. Nausea and gastrointestinal issues were frequently reported. However, a notable detail from the trial involved the reason some participants discontinued: Eli Lilly recorded that several patients withdrew due to experiencing what they perceived as “excessive weight loss.”
Investors are now looking ahead to 2026. Results from seven additional Phase 3 studies are expected that year, which will pave the way for official regulatory approval. In the nearer term, fourth-quarter earnings scheduled for late January or early February 2026 will provide insight into how strongly current Zepbound sales are already driving corporate growth.
Ad
Eli Lilly Stock: Buy or Sell?! New Eli Lilly Analysis from December 12 delivers the answer:
The latest Eli Lilly figures speak for themselves: Urgent action needed for Eli Lilly investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 12.
Eli Lilly: Buy or sell? Read more here...
